Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

UnitedHealth, PacifiCare To Pursue Separate Courses For Part D After Merger

  • News

Executive Summary

UnitedHealth Group and PacifiCare will adopt separate strategies for introducing Medicare Part D prescription drug plans notwithstanding a July 6 announcement that the two health care providers will merge

You may also be interested in...



UnitedHealth Will Be More Aggressive In Part D Pharmaceutical Contracting

UnitedHealth Group plans to leverage the scale of its Part D business to produce "significant decreases" in its cost structure for the program in 2007, Chairman and CEO William McGuire said during the company's second quarter earnings call July 19

UnitedHealth Will Be More Aggressive In Part D Pharmaceutical Contracting

UnitedHealth Group plans to leverage the scale of its Part D business to produce "significant decreases" in its cost structure for the program in 2007, Chairman and CEO William McGuire said during the company's second quarter earnings call July 19

Ovations/Walgreens Deal Reflects Importance Of Retail In Medicare Part D

Ovations' partnership with Walgreens on its Medicare prescription drug plan underscores the importance of a strong retail presence in the Part D market

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS046065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By